약제 용출 스텐트 시장 - 세계 예측(2026-2032년)

The Drug Eluting Stent Market is projected to grow by USD 11.22 billion at a CAGR of 8.46% by 2032.

Drug Eluting Stents Advance Coronary Intervention Outcomes

The drug eluting stent market is central to modern interventional cardiology, supporting percutaneous coronary intervention for patients with coronary artery disease by combining mechanical vessel scaffolding with controlled local delivery of antiproliferative drugs. Compared with early bare-metal stents, contemporary drug eluting stents are designed to reduce neointimal hyperplasia and restenosis while improving long-term vessel patency. Clinical adoption is being shaped by the global burden of ischemic heart disease, aging populations, diabetes prevalence, hypertension, obesity, smoking exposure, and the expanding use of minimally invasive cardiac procedures. Current innovation priorities include thinner struts, biocompatible or biodegradable polymers, improved drug-release kinetics, enhanced deliverability in complex lesions, and stent platforms suitable for high-risk anatomical and clinical profiles. Regulatory scrutiny remains rigorous because device safety, late thrombosis risk, dual antiplatelet therapy requirements, and real-world performance remain decisive factors for hospitals, physicians, payers, and health authorities.

Transformative Shifts Redefining Drug Eluting Stent Adoption

The drug eluting stent landscape is undergoing a structural shift from device-centric innovation toward evidence-led, patient-specific coronary care. Interventional cardiology programs are increasingly prioritizing outcomes in complex percutaneous coronary intervention, including multivessel disease, left main lesions, bifurcations, calcified vessels, long lesions, diabetes-associated coronary disease, and patients at high bleeding risk. This shift is increasing demand for stent systems that combine radial strength, flexibility, low crossing profile, conformability, and predictable drug release. Health systems are also placing greater emphasis on real-world evidence, post-market surveillance, and registry-based performance monitoring to validate outcomes beyond controlled trials. Procedural standards are changing as intravascular imaging, physiology-guided decision-making, lesion preparation technologies, and optimized antiplatelet strategies become more integrated with drug eluting stent implantation. At the same time, reimbursement frameworks and value-based procurement are encouraging device selection based on measurable clinical benefit, total episode-of-care efficiency, and reduced repeat revascularization rather than product features alone.

Cumulative Impact of Artificial Intelligence on Stent Innovation

Artificial intelligence is cumulatively influencing the drug eluting stent ecosystem across discovery, design, clinical workflow, and post-procedure monitoring. In device development, AI-enabled modeling can support stent geometry optimization, polymer behavior assessment, hemodynamic simulation, and prediction of restenosis or thrombosis-related risk factors under varied vessel conditions. In clinical practice, machine learning tools are increasingly being explored to improve coronary image interpretation, quantify lesion morphology, support calcium assessment, and assist procedural planning when combined with angiography, intravascular ultrasound, optical coherence tomography, or computed tomography data. AI can also strengthen patient stratification by integrating comorbidities, medication adherence patterns, bleeding risk, renal function, and prior cardiovascular events to guide stent selection and antiplatelet therapy decisions. For healthcare systems, AI-supported registry analytics and post-market surveillance can identify safety signals, procedural variation, and long-term outcome patterns more rapidly. However, adoption depends on validated algorithms, transparent clinical evidence, interoperability with cath lab systems, cybersecurity safeguards, bias mitigation, and compliance with medical device software regulations.

Key Regional Insights Across Global Drug Eluting Stent Demand

Asia-Pacific is a high-priority region for drug eluting stents due to rising cardiovascular disease burden, expanding catheterization laboratory infrastructure, growing insurance coverage, and increasing access to percutaneous coronary intervention in China, India, Japan, South Korea, Australia, and Southeast Asian markets. North America remains defined by advanced interventional cardiology capabilities, robust clinical guideline implementation, high use of intravascular imaging in complex cases, and stringent evidence expectations from regulators and payers. Latin America is progressing through broader access to cardiac care in urban centers, although affordability, reimbursement variation, and unequal specialist distribution continue to influence procedure access. Europe benefits from mature cardiology networks, strong clinical research activity, and harmonized quality expectations under evolving medical device regulations, with adoption shaped by public procurement discipline and national health technology assessment. The Middle East is expanding tertiary cardiac care capacity through specialized heart centers, medical tourism initiatives, and investments in advanced cath lab infrastructure, particularly in high-income Gulf economies. Africa presents an emerging access landscape where coronary intervention growth is concentrated in major metropolitan hospitals, while infrastructure gaps, workforce constraints, and affordability challenges continue to affect drug eluting stent availability.

Key Group Insights Shaping Stent Access and Procurement

ASEAN markets are experiencing gradual growth in drug eluting stent utilization as healthcare systems invest in tertiary cardiac centers, training programs, and broader cardiovascular screening, although procurement policies and out-of-pocket costs remain important adoption factors. The GCC is distinguished by high cardiovascular risk linked to diabetes, obesity, and sedentary lifestyles, alongside strong investment in specialty hospitals and advanced interventional cardiology infrastructure. The European Union maintains a highly regulated and evidence-driven environment where device performance, clinical safety, traceability, and post-market evidence are critical to market access and hospital procurement. BRICS economies combine substantial disease burden with expanding domestic healthcare capacity, making affordability, local manufacturing policy, public-sector tendering, and urban-rural access disparities important considerations. G7 countries generally demonstrate mature adoption of contemporary drug eluting stent platforms, supported by established reimbursement systems, clinical registries, and advanced procedural capabilities. NATO member countries overlap significantly with developed healthcare systems in North America and Europe, where hospital readiness, regulatory alignment, and supply chain resilience are increasingly relevant to cardiovascular device procurement and continuity of care.

Key Country Insights for Drug Eluting Stent Market Dynamics

The United States leads in advanced percutaneous coronary intervention practice, supported by specialized cardiac centers, clinical guideline adoption, and extensive use of real-world evidence in evaluating drug eluting stent performance. Canada emphasizes equitable access through publicly funded healthcare systems, with adoption shaped by provincial procurement, clinical appropriateness, and outcomes-based evaluation. Mexico is expanding interventional cardiology capacity in major cities, while access differences between public and private care settings influence device utilization. Brazil has a large cardiovascular disease burden and established tertiary hospitals, with reimbursement structures and regional disparities affecting access to advanced stent technologies. The United Kingdom relies on guideline-driven coronary care, national clinical audits, and cost-effectiveness assessments to guide adoption. Germany is a major European center for interventional cardiology, supported by high procedural capability, strong hospital infrastructure, and rigorous quality standards. France combines established cardiovascular care pathways with reimbursement oversight and clinical evidence requirements. Russia has invested in cardiovascular centers and acute coronary syndrome networks, though regional access and procurement dynamics remain important. Italy and Spain have mature cardiology systems, with adoption shaped by regional health authority budgets and clinical practice variation. China is rapidly advancing coronary intervention capacity through hospital expansion, physician training, domestic device development, and large patient volumes. India shows rising demand driven by coronary artery disease prevalence, urban cardiac care expansion, and affordability-sensitive purchasing. Japan is characterized by high procedural sophistication, aging demographics, and strong emphasis on safety and device quality. Australia maintains evidence-led adoption within a regulated healthcare environment and advanced specialist networks. South Korea combines high technology readiness, sophisticated hospitals, and strong clinical adoption of contemporary interventional cardiology techniques.

Actionable Recommendations for Drug Eluting Stent Leaders

Industry leaders should prioritize clinically differentiated drug eluting stent platforms that address complex lesions, high bleeding risk patients, diabetic populations, and aging patients with multiple comorbidities. Product development should focus on thinner struts, durable deliverability, optimized polymer biocompatibility, controlled drug elution, and compatibility with imaging-guided and physiology-guided PCI workflows. Evidence strategies should extend beyond pivotal trials to include real-world registries, longer-term follow-up, subgroup analyses, and transparent safety reporting on restenosis, stent thrombosis, target lesion failure, and repeat revascularization. Commercial teams should align with hospital value committees by demonstrating procedural efficiency, lifecycle value, supply reliability, and training support. Regional strategies must reflect reimbursement maturity, procurement systems, local regulatory requirements, and affordability constraints, particularly in emerging economies. Leaders should also invest in physician education, AI-enabled procedural planning partnerships, digital post-market surveillance, and supply chain resilience to maintain trust across cath lab networks and healthcare systems.

Research Methodology Grounded in Verified Evidence

This executive summary is developed using a structured secondary research methodology focused on verified clinical, regulatory, and healthcare system evidence. The approach includes analysis of peer-reviewed cardiology literature, interventional cardiology guidelines, public health data on coronary artery disease and cardiovascular risk factors, medical device regulatory documentation, hospital technology assessment practices, clinical trial findings, registry publications, and publicly available healthcare infrastructure indicators. Regional, group, and country-level insights are synthesized through cross-validation of disease burden, procedural adoption patterns, reimbursement context, cath lab capacity, regulatory expectations, and access barriers. The methodology excludes market sizing, market share, and forecasting and instead emphasizes evidence-backed qualitative analysis of adoption drivers, technology trends, policy influences, and clinical practice evolution. All findings are interpreted through the lens of drug eluting stent performance, patient outcomes, safety monitoring, and healthcare delivery readiness.

Conclusion: Evidence-Led Innovation Defines the Future of Stents

Drug eluting stents remain a foundational technology in the treatment of coronary artery disease, with continued relevance driven by improved clinical outcomes, minimally invasive intervention trends, and growing cardiovascular care needs worldwide. The sector is evolving through advanced materials, refined drug-release systems, imaging-guided implantation, AI-supported decision-making, and stronger post-market evidence expectations. Regional and country dynamics show that adoption is not uniform: mature healthcare systems emphasize evidence, safety, and value, while emerging markets focus on access expansion, affordability, infrastructure development, and physician training. Future competitive strength will depend on the ability to combine clinical differentiation with regulatory compliance, real-world performance transparency, procedural workflow integration, and reliable global supply. Stakeholders that align innovation with patient-specific care, long-term safety, and healthcare system value will be best positioned in the evolving drug eluting stent landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Eluting Stent Market, by Type

• 7.1. Introduction
• 7.2. Polymer Coated
  • 7.2.1. Biodegradable Polymer Coated
  • 7.2.2. Durable Polymer Coated
• 7.3. Polymer Free

8. Drug Eluting Stent Market, by Drug

• 8.1. Introduction
• 8.2. Biolimus Eluting
• 8.3. Everolimus Eluting
• 8.4. Paclitaxel Eluting
• 8.5. Sirolimus Eluting

9. Drug Eluting Stent Market, by Material Type

• 9.1. Introduction
• 9.2. Metallic Stents
  • 9.2.1. Stainless Steel Stents
  • 9.2.2. Cobalt Chromium Stents
• 9.3. Bioresorbable Stents
  • 9.3.1. Polymer Based Bioresorbable Stents
  • 9.3.2. Magnesium Based Stents

10. Drug Eluting Stent Market, by Application

• 10.1. Introduction
• 10.2. Coronary Artery Disease
• 10.3. Peripheral Vascular Disease

11. Drug Eluting Stent Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Hospitals

12. Drug Eluting Stent Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
• 12.3. Online

13. Drug Eluting Stent Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Drug Eluting Stent Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Drug Eluting Stent Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Acrostak AG
• 17.3. Amaranth Medical Inc.
• 17.4. B. Braun SE
• 17.5. Balton Sp. z o.o.
• 17.6. Biosensors International Group Ltd.
• 17.7. BIOTRONIK SE & Co. KG
• 17.8. Boston Scientific Corporation
• 17.9. Cardionovum GmbH
• 17.10. Concept Medical Inc.
• 17.11. Elixir Medical Corporation
• 17.12. Endocor GmbH
• 17.13. iVascular S.L.U.
• 17.14. JW Medical Systems
• 17.15. Lepu Medical Technology Beijing Co. Ltd.
• 17.16. Medinol Ltd.
• 17.17. Medtronic plc
• 17.18. Meril Life Sciences Pvt. Ltd.
• 17.19. MicroPort Scientific Corporation
• 17.20. OrbusNeich Medical Company Limited
• 17.21. Relisys Medical Devices Ltd.
• 17.22. Sahajanand Medical Technologies Limited
• 17.23. Sino Medical Sciences Technology Inc.
• 17.24. STENTYS SA
• 17.25. Terumo Corporation
• 17.26. Translumina GmbH